These findings suggest that depression may relate to an alteration of glutamatergic neurotransmission in this brain region since EAAT2 facilitates astrocytic glutamate reuptake, while KAT enzymes produce KYNA, an NMDA receptor antagonist. Here, SLC1A2 is linked to depressive symptom measurement.